Manufacturing, Liquid Drug Products

Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility

July 02, 2020

The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.

Addressing Drug Shortages

April 15, 2020

Equipment and Processing Report

Civica Rx plans redundant manufacturing capacity to relieve and prevent shortages of generic, sterile injectable drugs.

Recipharm Expands Indian Injectable Dosage Form Capabilities

November 20, 2019

Through a partnership with the Sobti family, the CDMO will expand is injectable dosage form capabilities.

Thermo Fisher Scientific to Invest $24 Million to Expand Global Bioproduction Capabilities

November 06, 2019

The company will invest $24 million into its Inchinnan, Scotland, site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell-culture media.

Foamix Enters Manufacturing Agreement with ASM Aerosol-Service for Topical Foam Treatment

October 24, 2019

Through the agreement, Foamix will have access to $20 million of financing to fund the commercial launches of the topical treatments.

Challenges for Compound and Small-Batch Aseptic Manufacturing

October 17, 2019

Ready-to-use components help compounders and manufacturers of small batches overcome economy-of-scale limitations in aseptic GMP manufacturing.

Nephron, UofSC Researchers Collaborate on Automation

September 16, 2019

Nephron Pharma and the University of South Carolina plan to build a sterile compounding lab at the University for research and training.

Robotics Solve Aseptic Filling Challenges

September 01, 2018

Automated robotic arms manipulate nested trays and containers inside closed aseptic filling systems.

Pfizer Recalls Children’s Advil

August 28, 2018

Pfizer Consumer Healthcare is recalling one lot of Children’s Advil Suspension Bubble Gum Flavored 4 FL OZ Bottle because of improperly marked dosage cups.

FDA Approves First Drug for Rare Eye Disease

August 24, 2018

Dompé Farmaceutici’s Oxervate (cenegermin), a topical eye drop, is the first treatment approved by the agency for neurotrophic keratitis, a rare disease affecting the cornea.